Alvotech マネジメント
マネジメント 基準チェック /34
Alvotechの CEO はLisa Graverで、 Mar2026年に任命され、 の在任期間は 1 年未満です。 は、会社の株式の0.007%を直接所有しており、その価値は$ 71.52K 。経営陣と取締役会の平均在任期間はそれぞれ1.2年と5.6年です。
主要情報
Lisa Graver
最高経営責任者
US$186.0k
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | less than a year |
| CEOの所有権 | 0.007% |
| 経営陣の平均在職期間 | 1.2yrs |
| 取締役会の平均在任期間 | 5.6yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.
ナラティブの更新 • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.ナラティブの更新 • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Seeking Alpha • Apr 10
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Summary Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers. Risks center on regulatory delays and high leverage (net debt/aEBITDA 9.3x), which could cap valuation and trigger corrections. Read the full article on Seeking Alpha
ナラティブの更新 • Mar 31
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.ナラティブの更新 • Mar 17
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.ナラティブの更新 • Mar 03
ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.ナラティブの更新 • Feb 17
ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.ナラティブの更新 • Feb 03
ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.ナラティブの更新 • Jan 20
ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.ナラティブの更新 • Jan 05
ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.ナラティブの更新 • Dec 17
ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.ナラティブの更新 • Dec 03
ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.分析記事 • Nov 20
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...ナラティブの更新 • Nov 19
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.分析記事 • Nov 09
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...分析記事 • Nov 06
Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...ナラティブの更新 • Nov 05
ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.分析記事 • May 25
Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...分析記事 • May 15
Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...新しいナラティブ • May 05
Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.分析記事 • Apr 08
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...Seeking Alpha • Nov 21
Alvotech's Position In The Coming Biosimilar Gold Rush
Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Alvotech: Steady Progress Offers A Good Chance Of Upside
Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking Alpha分析記事 • May 28
Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
Celebrations may be in order for Alvotech ( NASDAQ:ALVO ) shareholders, with the analysts delivering a significant...Seeking Alpha • Apr 25
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Summary Alvotech has received FDA approval for its biosimilar drugs Simlandi and Selarsdi, allowing the company to compete in the biosimilar market for Humira and Stelara. The company's stock price initially dropped after the FDA rejected Simlandi in 2023, but has since recovered. Alvotech's outlook for 2024 and 2025 is positive, with projected revenues of $300-$400 million and potential growth in the biosimilar market. Q1 2024 earnings will be announced on May 22 and have the potential to exceed Wall Street's expectations, in my view, setting the company on a long-term path to valuation growth, although significant headwinds remain in play. Read the full article on Seeking Alpha分析記事 • Apr 03
Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Alvotech ( NASDAQ:ALVO ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...分析記事 • Mar 24
Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Alvotech ( NASDAQ:ALVO ) just released its latest yearly report and things are not looking great. It was not a great...CEO
Lisa Graver (53 yo)
less than a year
在職期間
US$186,000
報酬
Ms. Lisa Graver served as Chief Executive Officer of Alvogen, Inc. until December 2025. She was a Non-Executive Director of Alvotech from June 16, 2022 until March 31, 2025 and serves as its Chief Executiv...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Executive Chairman | 7.3yrs | US$2.89m | データなし | |
| Chief Executive Officer | less than a year | US$186.00k | 0.0068% $ 71.5k | |
| Chief Financial Officer | less than a year | データなし | データなし | |
| Chief Operating Officer | 1.3yrs | データなし | 0.049% $ 520.6k | |
| Chief Information Officer | less than a year | データなし | データなし | |
| Vice President of Investor Relations & Global Communications | no data | データなし | データなし | |
| General Counsel | 3.3yrs | データなし | 0% $ 0 | |
| Head of Global Communications | no data | データなし | データなし | |
| Senior Vice President of Global Talent & People Experience | 1.3yrs | データなし | データなし | |
| Chief Quality & Regulatory Officer | 2.3yrs | データなし | データなし | |
| Chief Strategy Officer | 1.2yrs | データなし | データなし | |
| Vice President & Head of Business Development | less than a year | データなし | データなし |
1.2yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: ALVOの経営陣は 経験豊富 とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Executive Chairman | 7.3yrs | US$2.89m | データなし | |
| Director | 1.9yrs | US$149.00k | 0.00075% $ 7.9k | |
| Non-Executive Director | 7.3yrs | データなし | データなし | |
| Non-Executive Director | 3.9yrs | データなし | データなし | |
| Independent Non-Executive Deputy Chairman | 7.3yrs | US$307.00k | 0.35% $ 3.7m | |
| Independent Non-Executive Director | 3.9yrs | US$241.00k | 0.0068% $ 71.5k |
5.6yrs
平均在職期間
59yo
平均年齢
経験豊富なボード: ALVOの 取締役会 は 経験豊富 であると考えられます ( 5.6年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 10:00 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Alvotech 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Andrew Baum | Citigroup Inc |
| Peter Verdult | Citigroup Inc |